These findings warrant prospective validation and mechanistic dissection of the TMPRSS6-NEO1-sHJV pathway, and they suggest that therapeutic modulation of this axis may mitigate iron-related morbidity in childhood hematologic malignancies. This evidence concerns the gene TMPRSS6 and hematologic disorder.